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Supplementary Information
Biomarkers for multiple sclerosis determined by metabolomic profiling using coupled UHPLC-MS Sean Ward, Michael I. Page and Nicholas T. Powles Figure 1 PCA plot of raw data in MPP for plasma analysis of multiple sclerosis (blue), neuropathic pain (grey), multiple sclerosis and neuropathic pain (brown), control group (red) and QC injections (green). The principle component is plotted on the X-axis and represents 17% of data variation. Component 2 on the Y-axis represents 11% of the variation and component 3 on the Z-axis 6% of the variation. 
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The project aim was to identify differences in the metabolomic profiles in the serum of patients with multiple sclerosis (MS), those with neuropathic pain (NP) and those with both MS and NP compared with controls and to identify potential biomarkers of each disease state. Metabolomic profiling was performed using ultra-high-performance liquid chromatography coupled to mass spectrometry and the data analysis involved parametric methods, principal component analysis, and discriminating filter analysis to determine the differences between disease and control serum samples.
Agilent software Profinder and Mass Profiler Professional (MPP) were used to compare LC-MS data generated from the blood plasma of people suffering with multiple sclerosis with an age and gender matched control group. This was an un-targeted approach which led to the discovery of two compounds, sphingosine and dihydrosphingosine that were found to be lower in the blood of people suffering from multiple sclerosis. These compounds were searched in a larger sample set and found to follow the same trend of being lower in the disease group. It may be possible to use the concentration of these compounds in the blood as a marker of the disease. The project aim was to identify differences in the metabolomic profiles in the serum of patients with multiple sclerosis (MS), those with neuropathic pain (NP) and those with both MS and NP compared with controls and to identify potential biomarkers of each disease state. Metabolomic profiling was performed using ultra-high-performance liquid chromatography coupled to mass spectrometry and the data analysis involved parametric methods, principal component analysis, and discriminating filter analysis to determine the differences between disease and control serum samples.
Sphingosine and dihydrosphingosine were identified as significant biomarkers.
Introduction
There is a long recorded history of people suffering from multiple sclerosis (MS) which spans back centuries before it was given its modern name. People who developed a progressive paralysis would be diagnosed as suffering from paraplegia, a general diagnosis which covered many different neurological disorders. This loss of T cell regulation leads to the T cells becoming activated, proliferating and circulating throughout the body. These T cells then produce adhesion molecules and changes in the endothelia which in turn allow access into the CNS across the blood brain barrier. 5 The epidemiology of multiple sclerosis reveals two consistent features, that the disease clusters in families and that its frequency depends on which part of the world you live in, implying that there might be a genetic and an environmental component to the disease. 6 The screening of the genome from tens of thousands of multiple sclerosis sufferers in comparison to a control group has revealed more than 100 common variables of genes in the MS In recent years evidence that environmental factors which may affect MS to the greatest extent seems to be related to the gut microbiota as MS sufferers have an increased risk of gut permeability and inflammatory bowel disease which suggests that there may be a connection between the gut and the CNS. 10 It has also been shown that Pseudomonas peptides can activate myelin basic protein specific T cells which have been cloned from MS patients, but the difficulty in linking a specific microorganism with MS is that there are numerous microbial sequences that can activate the myelin basic protein specific T cells from MS patients.
11
Chlamydia pneumonia is commonly found in the cerebrospinal fluid of people suffering from MS and has been shown to induce the disease in an animal model. 12 Finally, there have been proposed links with mitochondrial dysfunction and multiple sclerosis along with other neurological diseases such as Alzheimer's and Parkinson's 13 .
In summary, the full understanding of the causes of MS is far from complete. The metabolomics analysis of pathways combined with the identification and quantification of small molecules in disease patients may help to solve this problem. Liquid chromatography mass spec (LC-MS) is growing in popularity in the field of metabolomics 14 but is highly dependent on both the analytical method and data analysis steps. 15 The use of metabolomics techniques has found metabolic differences between control groups and people with MS using GC-MS and LC-MS. 16 Herein LC-MS of blood plasma samples from people suffering with multiple sclerosis (MS), neuropathic pain (NP) and multiple sclerosis with neuropathic pain (MSNP) along with a control group was used to identify specific biomarkers which could be a useful diagnostic tool.
Results
For the comparison of LC-MS data sets the features first need to be extracted using their accurate mass and then be aligned by retention time. 17 Feature extraction and data alignment is a critical 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 There are 25 entities that differentiate the disease groups from the control group; 4 that only differ in the neuropathic pain group, 11 in the multiple sclerosis with neuropathic pain group and 1 entity that only differs in the multiple sclerosis group. There are 6 entities that differ in all of the disease groups and only 2 that differ in both the multiple sclerosis and neuropathic pain groups compared with the control group. There is just 1 entity that differs in both the multiple sclerosis and multiple sclerosis with neuropathic pain groups and this difference in the abundance of this entity is common to all of the samples collected from people with multiple sclerosis. Another study 28 found differences in lipid composition in the white and grey matter of multiple sclerosis patients. Patients with active multiple sclerosis showed higher levels of phosphorylated sphingolipid but lower sphingolipid levels in both white and grey matter. This is in agreement with the results found herein from blood plasma analysis. In patients with inactive multiple sclerosis only white matter had increased phosphorylation of sphingolipids.
One of these was phosphatidylcholine which on hydrolysis yields lysophosphatidylcholine 29 which can be used for the in vitro demyelination of nerve fibres 30 which could be another contributing factor to the progression of the disease.
The drug fingolimod (2) has shown promise in clinical trials for the treatment of multiple sclerosis. Fingolimod is a sphingosine analogue which is phosphorylated in the body to form fingolimodphosphate, this resembles sphingosine-1-phosphate (S1P).
Currently five S1P receptors have been discovered (S1P [1] [2] [3] [4] [5] To further investigate the difference in sphingosine concentration between a control group and a multiple sclerosis group a larger sample set was used consisting of 30 plasma samples from people with multiple sclerosis (15 of which also had neuropathic pain) were analysed along with 60 age and gender matched control samples and the peak area for sphingosine integrated using Profinder . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Analytical Methods   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Manuscript ID: AY-ART-08-2017-001922 TITLE: Biomarkers for multiple sclerosis determined by metabolomic profiling using coupled UHPLC-MS
Response to reviewers comments
1. The title of this article did not highlight this study's result and focus on the concentration of sphingosine and dihydrosphingosine in MS blood. Title amended 2. The reason why the author choose the mass of 299.2818 from the 25 differentiating compounds as the biomarker could not be found in the article.
Text modified to explain this. 3. The author did not clearly explained in this article why the entity list needed to be reprocessed.
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